The North American Preventive Vaccine Market size was worth USD 16.40 Billion in 2021 and is expected to reach USD 29.63 billion by the end of 2026, growing at a CAGR of 12.56% between 2021 to 2026.
While the preventive vaccine accounts for only 5 % of the global pharmaceuticals market, there has been substantial growth in recent years due to rising incidences of HIV cases and cancer. World Health Organization growth estimations indicate the market may increase at a tremendous rate by introducing new therapeutic, preventive, and adult vaccines.
Vaccination is the process of injecting the vaccine given to stimulate the immune system of an individual. Despite being a small one, the Vaccine market is being exploited by multinational companies due to its growth at a faster rate. There are as many as 120 new vaccines in the pipeline of many major companies and are set to hit the market worldwide in the coming years.
The rise in the frequency of occurrence of infectious diseases, the invention of new vaccines for every other disease, and the increase in the funding for vaccine development help drive the growth of the preventive vaccine market. The rise of investments in the R&D department by the major players, technological advancements, and increasing occurrence of the disease is also helping the growth of the market.
Factors like huge capital investment, strict regulatory policies, and the high cost of treatment hinder the growth of the market.
This research report segmented and sub-segmented the North American Preventive Vaccines Market into the following categories:
By Vaccine Type:
By End-User:
By Country:
Regionally, North America enjoys the major share of the therapeutic vaccine market due to the presence of advanced and active R&D establishments in the region. Multinational vaccine companies have historically conducted much of the innovation, research, and development in vaccine production.
The most promising companies operating in the North American Preventive Vaccine Market profiled in this report are GlaxoSmithKline, PLC, Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC., Pfizer, Inc. and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Vaccine Type
5.1.1 Live, Attenuated Vaccines
5.1.2 Inactivted Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Subunit vaccines
5.1.5 Conjugate vaccines
5.1.6 DNA vaccines
5.1.7 Recombinant vector vaccines
5.2 By End User
5.2.1 Paediatric Vaccine
5.2.1.1 Pneumococcal
5.2.1.2 MMR
5.2.1.3 Varicella
5.2.1.4 Hepatitis
5.2.1.5 Poliovirus
5.2.1.6 HIB
5.2.1.7 Others
5.2.2 Adult Vaccines
5.2.2.1 Influenza
5.2.2.2 Cervical Cancer
5.2.2.3 Hepatitis
5.2.2.4 Zoster
5.2.2.5 Others
6.1 Introduction
6.2 United States
6.3 Canada
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSmithKline, plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune, LLC
8.9 Pfizer, Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
